Descripción del proyecto DEENESFRITPL Las gotas para los ojos pueden interrumpir la respuesta de autoinmunidad en enfermedades oculares graves Las enfermedades inflamatorias oculares, también denominadas uveítis, son un grupo variado de enfermedades inflamatorias de origen autoinmune o infeccioso que pueden producir ceguera. A pesar del progreso realizado mediante el uso de terapias con esteroides, no existe un tratamiento efectivo y el uso a largo plazo de esteroides puede provocar complicaciones graves. TRS ha desarrollado una molécula patentada inspirada en la naturaleza que interrumpe el mecanismo autoinmune que provoca las enfermedades. De este modo, tiene el potencial de tratar la progresión de las enfermedades y no solo mejorar los síntomas. La tecnología estará disponible en forma de gotas e inyecciones para tratar todas las partes del ojo en función de cada enfermedad concreta. La financiación europea está respaldando los ensayos clínicos, cuyos resultados ayudarán a asegurar la financiación para la comercialización. Mostrar el objetivo del proyecto Ocultar el objetivo del proyecto Objetivo Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness. Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases. Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market. In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicineophthalmologyglaucomamedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesbasic medicineimmunologysocial sciencessociologygovernancetaxation Palabras clave Inflammation blinding condition biomimetics uveitic glaucoma Programa(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Tema(s) EIC-SMEInst-2018-2020 - SME instrument Convocatoria de propuestas H2020-EIC-SMEInst-2018-2020 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEInst-2018-2020-2 Régimen de financiación SME-2 - SME instrument phase 2 Coordinador TARSIER PHARMA LTD Aportación neta de la UEn € 2 423 050,00 Dirección 19 YAHALOM ST. 3093765 Zichron Yaakov Israel Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 3 461 500,00
